Israel’s Eloxx Pharmaceuticals Raises $24M

June 15, 2017 | Israeli bio-pharmaceutical company Eloxx  has raised $24 million from Catalyst CEL Fund, Israeli venture capital fund for life sciences Pontifax, and others. The company develops treatments for patients with rare genetic diseases triggered by mutations like Cystic Fibrosis and Cystinosis. Founded in 2013 by Dr. Silvia Noiman, Eloxx recently merged with Sevion Therapeutics and became a Sevion subsidiary. Sevion will use the name Eloxx and attempt to list its shares on Nasdaq. [Photo: GeneG]